ChabioTech Posts 1.27 Trillion Won in 2025 Revenue... Operating Loss Due to Expanded Investment

21% Year-on-Year Growth
Sustained Performance in Global Healthcare Businesses Including the US, Australia, and Singapore

On February 27, ChabioTech announced that its consolidated revenue for the previous year reached 1.2683 trillion won, marking a 21% increase compared to the prior year. Due to expanded investment in research and development, the company recorded an operating loss of 47.5 billion won.

Cha Biotech company logo image. Cha Biotech

The revenue growth was driven by improved performance from domestic subsidiaries and the expansion of healthcare businesses overseas, including in the United States and Australia. The balanced growth of the global hospital network and healthcare service businesses also contributed to this result.

The company posted a net loss for the year of 139.2 billion won. This was due to non-cash accounting factors such as fair value assessments of convertible bonds (CB), bonds with warrants (BW), exchangeable bonds (EB), and redeemable convertible preferred shares (RCPS), as well as accounting interest expenses and foreign exchange losses resulting from currency fluctuations.

On a separate basis, revenue stood at 62.2 billion won, up 15% year-on-year. Growth was seen in immune cell and stem cell storage, genomic analysis, and healthcare IT businesses. Due to the expansion of R&D personnel and increased pipeline development expenses, the separate operating loss amounted to 4.7 billion won.

The company is currently building the 'CGB (Cell Gene Bioplatform),' a global cell and gene therapy CDMO production base. This facility will be established as an integrated bio-infrastructure, including a CGT CDMO, cGMP manufacturing facilities, a CRO, and a biobank.

ChabioTech also plans to accelerate the development of its regenerative medicine pipeline. The strategy is to enhance competitiveness in the cell therapy business by advancing clinical trials for autologous NK cell therapy 'CHANK-101' and tumor-infiltrating lymphocyte (TIL) therapy 'CHATIL-101'. The company aims to expand its AI and data-driven healthcare business through collaboration with firms such as LG CNS and Hanwha financial affiliates. Additionally, leveraging the acquisition of Kakao Healthcare, ChabioTech is working to establish a data ecosystem that integrates medical care, research, and clinical activities.

This content was produced with the assistance of AI translation services.